West Point Optical Group and Verséa Ophthalmics Collaborate on BIOVANCE Supply Agreement

West Point Optical Group, LLLC (WPOG) and Verséa Ophthalmics, Inc announced in a press release that the companies have entered into a partnership supply agreement in which Verséa Ophthalmics will be the exclusive provider of its Biovance and Biovance 3L Ocular products as the only human amniotic membrane tissue products used within WPOG practices to support the treatment of ocular surface disease and ocular surgical applications.

Biovance and Biovance 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. Biovance 3L Ocular is acellular and consists of three layers of amniotic basement membrane that supports treatment of advanced ocular surface disease. As a barrier membrane, Biovance 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures, many of which are relevant to WPOG practices and their eye care professional teams.

Read the full press release here.